Arixtra (Mylan Institutional LLC)
Welcome to the PulseAid listing for the Arixtra drug offered from Mylan Institutional LLC. This Factor Xa Inhibitor [EPC],Factor Xa Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Mylan Institutional LLC |
NON-PROPRIETARY NAME: | fondaparinux sodium |
SUBSTANCE NAME: | FONDAPARINUX SODIUM |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Factor Xa Inhibitor [EPC],Factor Xa Inhibitors [MoA] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-05-06 |
END MARKETING DATE: | 0000-00-00 |
Arixtra HUMAN PRESCRIPTION DRUG Details:
Item Description | Arixtra from Mylan Institutional LLC |
LABELER NAME: | Mylan Institutional LLC |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 2.5(mg/.5mL) |
START MARKETING DATE: | 2015-05-06 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 67457-592_8914754d-8bc2-488f-ac60-c97f8f139673 |
PRODUCT NDC: | 67457-592 |
APPLICATION NUMBER: | NDA021345 |
Other FONDAPARINUX SODIUM Pharmaceutical Manufacturers / Labelers: